MetaVia (MTVA) investor relations material

Executive summary

• Focused on developing novel pharmaceuticals for cardiometabolic diseases, with two main programs: vanoglipel (MASH, T2DM) and DA-1726 (obesity, MASH).

• Achieved key milestone with first patient dosed in Phase 1 Part 3 study of DA-1726 for obesity, evaluating higher dose regimens with data expected in Q4 2026.

• 48 mg Phase 1 data showed 9.1% weight loss, improved glucose control, and direct liver benefit with favorable safety profile.

• Strengthened intellectual property for DA-1726 and vanoglipel, with patent protection extending to at least 2041 and 2035, respectively.

• Four legacy programs are not being advanced and are considered for out-licensing or divestiture.

Financial highlights

• Net loss of $3.8 million for Q1 2026, compared to $3.7 million in Q1 2025.

• Total operating expenses were $4.0 million, up slightly year-over-year, driven by higher G&A costs.

• R&D expenses decreased 9.7% to $2.1 million, while G&A expenses increased 23.4% to $1.9 million.

• Cash and cash equivalents totaled $13.7 million as of March 31, 2026, up from $10.2 million at year-end 2025.

• Accumulated deficit reached $152.7 million.

Outlook and guidance

• Expectation of continued net losses and negative cash flows due to ongoing clinical trials.

• Cash position expected to fund operations into Q4 2026.

• Substantial doubt exists about the ability to continue as a going concern within one year without additional funding.

• Data from Phase 1 Part 3 titration studies of DA-1726 expected in Q4 2026.

• End-of-Phase 2 meeting with FDA for vanoglipel in MASH is being scheduled.